Results 101 to 110 of about 2,667 (188)

Translating biomarker insights into practice: a path forward in TA-TMA management

open access: yesFrontiers in Medicine
Recent advances in the management of transplant-associated thrombotic microangiopathy (TA-TMA) include the harmonization of diagnostic criteria and the identification of high-risk disease features.
Sonata Jodele, Eleni Gavriilaki
doaj   +1 more source

Ravulizumab and Efgartigimod in Myasthenia Gravis

open access: yesNeurology Neuroimmunology & Neuroinflammation
Finanziert durch den Open-Access-Publikationsfonds der Universität Münster.
Frauke Stascheit   +16 more
openaire   +4 more sources

mRNA-1273/ravulizumab [PDF]

open access: yesReactions Weekly, 2021
openaire   +1 more source

Refocusing generalized myasthenia gravis : Patient burden, disease profiles, and the role of evolving therapy [PDF]

open access: yes
Generalized myasthenia gravis (gMG) continues to present significant challenges for clinical management due to an unpredictable disease course, frequent disease fluctuations, and varying response to therapy.
Cortés-Vicente, Elena   +5 more
core   +1 more source

Successful haploidentical hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with severe pancytopenia developed after long‐term aplastic anemia treatment

open access: yesClinical Case Reports
Key Clinical Message Haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide is an alternative treatment for aplastic anemia–paroxysmal nocturnal hemoglobinuria (PNH) syndrome with poor prognostic factors ...
Kazuki Sakurai   +6 more
doaj   +1 more source

New drugs for acute kidney injury. [PDF]

open access: yes
Acute kidney injury (AKI) presents a significant challenge in the management of critically ill patients, as it is associated with increased mortality, prolonged hospital stays, and increased healthcare costs.
Hariri, Geoffroy, Legrand, Matthieu
core   +1 more source

Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study

open access: yesHealth and Quality of Life Outcomes
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder. Symptoms such as fatigue can have a substantial impact on patients’ physical activity levels, sleep, quality of life, and work productivity. Ravulizumab treatment can
Elizabeth A. Griffiths   +6 more
doaj   +1 more source

Treating myasthenia gravis beyond the eye clinic [PDF]

open access: yes
Myasthenia gravis (MG) is one of the most well characterised autoimmune disorders affecting the neuromuscular junction with autoantibodies targeting the acetylcholine receptor (AChR) complex.
Jacob, Saiju
core   +1 more source

Two‐decade battle with myasthenia gravis: A breakthrough case report on the long‐term success with eculizumab and ravulizumab treatment

open access: yesClinical Case Reports
Key Clinical Message This unique case of generalized myasthenia gravis shows sustained stability of a patient's condition for 3 years with eculizumab/ravulizumab treatment following 16 years of refractory disease.
Stefan Quasthoff
doaj   +1 more source

A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS)

open access: yesTrials
Background Cardiac procedures, particularly those requiring cardiopulmonary bypass (CPB), are associated with the development of cardiac surgery-associated acute kidney injury (CSA-AKI).
Marlies Ostermann   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy